

Opportunities

Commercial opportunities

- Breakthrough technology for individualized cancer treatment
- The technology is protected by a strong portfolio of issued and pending patents
- First product launched in 2015
- Medicare (USA) approved in 2006 reimbursement of in-vitro test in patient cells for tailoring individualized treatment regimens. 2cureX will provide the first test that allows screening of the complete palette of combination therapies

2cureX company

2cureX has established an active network of clinical partners in Denmark and Germany with test sites in Copenhagen and Hamburg.

Bispebjerg Hospital, Copenhagen



Rigshospitalet, Copenhagen



Universitätsklinikum Hamburg Eppendorf, Hamburg



Contact details: Ole Thastrup, CEO
Tel: +45 2211 5399
e-mail: ot@2curex.com

Timm Jessen, CBO
Tel: +49 170 964 2915
e-mail: tj@2curex.com

2curex

A Novel Approach to Cancer Therapy



Matching individual patients with optimal combination chemotherapy

Therapy is selected by monitoring resistance and efficacy in cancer cells from the individual patient

Perspective

Breakthrough in design of combination therapy for the individual patient

2cureX is developing the first technology (2treat) that allows prospective testing of all potential combinations of approved and investigational drugs for resistance and efficacy in cancer cells from the individual patient.

The technology has been applied to solid cancers as colorectal, breast, pancreas and head & neck cancers.

The technology is implemented at hospitals in Denmark and Germany.

Improvement of treatment quality and cost efficiency

It is detrimental to the success of cancer treatment that the right therapy is given immediately. Implementation of the 2cureX test will assist in:


- Avoidance of progression to late-stage disease with dramatically worsen prognosis
- Eliminating cross resistance to subsequent treatment regimens
- Selection of combination therapy including investigational drugs for patients with late stage metastatic disease
- Increasing cost efficiency by offering expensive treatment regimens only to responsive patients

Concept and Technology

Concept

3D micro-tumors are established ex-vivo from resected tumor, metastasis or colonoscopy biopsies from the individual patient.

The micro-tumors show strong phenotypical and functional alignment with the patients tumor. With similar drug sensitivity and resistance.



IndiTreat test



In one 2treat test hundred of combinations of individual drugs will be tested for efficacy and resistance in the individual patient. Within 10 days, a complete efficacy/resistance profile will be provided to the oncologist.